Related Experiment Video

Updated: Jul 30, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and

Takahiro Inoue1, Sho Sekito1, Takumi Kageyama1

  • 1Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu 514-8507, Japan.

Cancers
|May 13, 2023
PubMed

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors show promise for treating prostate cancer with DNA damage repair (DDR) gene mutations. However, resistance can develop, necessitating further research into their mechanisms and tumor microenvironment effects.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Cancer cells often have DNA damage repair (DDR) defects, causing genomic instability.
  • This instability can create dependencies on specific DDR pathways, making them potential therapeutic targets.
  • Poly (ADP-ribose) polymerase (PARP) inhibitors exploit synthetic lethality in cancers with DDR gene mutations, such as BRCA1/2.

Purpose of the Study:

  • To review the mechanisms of action for PARP inhibitors in prostate cancer.
  • To discuss the clinical efficacy and limitations of PARP inhibitors in prostate cancer treatment.
  • To explore the impact of PARP inhibitors on the tumor microenvironment.

Main Methods:

  • Review of existing literature on PARP inhibitors and prostate cancer.
  • Analysis of clinical trial data, including the PROfound trial.
  • Examination of molecular mechanisms underlying PARP inhibitor action and resistance.

Main Results:

  • PARP inhibitors, like olaparib, demonstrate efficacy in prostate cancer patients with BRCA1/2 mutations.
  • Genomic instability from DDR gene inactivation can lead to resistance to PARP inhibitors.
  • The efficacy of PARP inhibitors is particularly noted in metastatic castration-resistant prostate cancer (mCRPC).

Conclusions:

  • PARP inhibitors represent a significant advancement in treating specific subtypes of prostate cancer.
  • Understanding resistance mechanisms is crucial for optimizing PARP inhibitor therapy.
  • Further investigation into the tumor microenvironment's role is needed to enhance treatment strategies.
Keywords:
BRCA1/2DNA damage repairPARP inhibitorprostate cancertumor microenvironment

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.2K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K